## UNITED STATES SECURITIES AND EXCHANGE COMMISSION November 20, 2009

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Rexahn Pharmaceuticals, Inc. File No. 001-34079- CF#23825

Rexahn Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from an Exhibit to a Form 8-K filed on September 21, 2009.

Based on representations by Rexahn Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1 through June 30, 2012

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jeffrey P. Riedler Assistant Director